MedPath

Early Rabies Vaccine Immunization in Primary School Children

Phase 3
Completed
Conditions
Rabies Prevention
Registration Number
NCT01107275
Lead Sponsor
Provincial Public Health Office, Phetchabun
Brief Summary

700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken for rabies virus neutralizing antibody determination on day 49. All subjects were randomized to receive 2 booster doses (the recommended vaccination schedule for pre-immunized individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood was taken before and after booster for up to one year.Safety and tolerability of the vaccine was assessed and persistence of immune response up to 1 year after the booster doses.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
703
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
rabies virus neuralizing antibody, assessed by RFFITseven days after the first booster dose

rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)

Secondary Outcome Measures
NameTimeMethod
rabies virus neuralizing antibody, assessed by RFFITimmediately before administration of the first booster dose

rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)

Trial Locations

Locations (1)

Phetchabun Province primary schools

🇹🇭

Phetchabun, Thailand

Phetchabun Province primary schools
🇹🇭Phetchabun, Thailand

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.